Selective targeting of the stress chaperome as a therapeutic strategy

Trends in Pharmacological Sciences

Volumn 35, Issue 11, 2014, Pages 592-603

  Taldone, Tony ^a   Ochiana, Stefan O ^a   Patel, Pallav D ^a   Chiosis, Gabriela ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

chemical tools; epigenetic regulation; HSP60; HSP70; HSP90; molecular chaperone

Indexed keywords

ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATE; ALVESPIMYCIN; ANSAMYCIN DERIVATIVE; BUFFER; CHAPERONE; DNA; HEAT SHOCK PROTEIN 90; LUMINESPIB; PROTEOME; RADICICOL; TUMOR NECROSIS FACTOR RECEPTOR; HEAT SHOCK PROTEIN;

ARTICLE; CELL FUNCTION; CELL MOTILITY; CHRONIC STRESS; CONTROLLED STUDY; DNA REPLICATION; DRUG MECHANISM; DRUG TARGETING; ENDOPLASMIC RETICULUM; EPIGENETICS; HUMAN; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN METHYLATION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; PROTEIN TARGETING; STRESS; SUMOYLATION; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMICAL STRUCTURE; CHEMISTRY; METABOLISM; MOLECULARLY TARGETED THERAPY;

ANIMALS; HEAT-SHOCK PROTEINS; HUMANS; MODELS, MOLECULAR; MOLECULAR CHAPERONES; MOLECULAR TARGETED THERAPY;

EID: 84908372066     PISSN: 01656147     EISSN: 18733735     Source Type: Journal    
DOI: 10.1016/j.tips.2014.09.001     Document Type: Review

References (122)

1. A. Finka, and P. Goloubinoff Proteomic data from human cell cultures refine mechanisms of chaperone-mediated protein homeostasis Cell Stress Chaperones 18 2013 591 605
2. Y.E. Kim Molecular chaperone functions in protein folding and proteostasis Annu. Rev. Biochem. 82 2013 323 355
3. H. Saibil Chaperone machines for protein folding, unfolding and disaggregation Nat. Rev. Cancer 13 2013 630 642
4. F.U. Hartl Molecular chaperones in protein folding and proteostasis Nature 475 2011 324 332
5. M.S. Hipp Proteostasis impairment in protein-misfolding and -aggregation diseases Trends Cell Biol. 24 2014 506 514
6. A. Marino-Enriquez Genome-wide functional screening identifies CDC37 as a crucial HSP90-cofactor for KIT oncogenic expression in gastrointestinal stromal tumors Oncogene 33 2014 1872 1876
7. E. Ruckova Alterations of the Hsp70/Hsp90 chaperone and the HOP/CHIP co-chaperone system in cancer Cell. Mol. Biol. Lett. 17 2012 446 458
8. K. Moulick Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90 Nat. Chem. Biol. 7 2011 818 826
9. K.B. Kaplan, and R. Li A prescription for 'stress' - the role of Hsp90 in genome stability and cellular adaptation Trends Cell Biol. 22 2012 576 583
10. S. Polier ATP-competitive inhibitors block protein kinase recruitment to the Hsp90-Cdc37 system Nat. Chem. Biol. 9 2013 307 312
11. C. Shipp Associations of HSP90 client proteins in human breast cancer Anticancer Res. 31 2011 2095 2101
12. C.L. McDowell Expression of Hsp90 chaperone proteins in human tumor tissue Int. J. Biol. Macromol. 45 2009 310 314
13. P. Muller C-terminal phosphorylation of Hsp70 and Hsp90 regulates alternate binding to co-chaperones CHIP and HOP to determine cellular protein folding/degradation balances Oncogene 32 2013 3101 3110
14. D. Sahu A potentially common peptide target in secreted heat shock protein-90alpha for hypoxia-inducible factor-1alpha-positive tumors Mol. Biol. Cell 23 2012 602 613
15. A. Walton-Diaz Contributions of co-chaperones and post-translational modifications towards Hsp90 drug sensitivity Future Med. Chem. 5 2013 1059 1071
16. M.E. Jakobsson Identification and characterization of a novel human methyltransferase modulating Hsp70 protein function through lysine methylation J. Biol. Chem. 288 2013 27752 27763
17. P. Cloutier A newly uncovered group of distantly related lysine methyltransferases preferentially interact with molecular chaperones to regulate their activity PLoS Genet. 9 2013 e1003210
18. H.S. Cho Enhanced HSP70 lysine methylation promotes proliferation of cancer cells through activation of Aurora kinase B Nat. Commun. 3 2012 1072
19. O.R. Lorenz Modulation of the Hsp90 chaperone cycle by a stringent client protein Mol. Cell 53 2014 941 953
20. F.J. Echtenkamp, and B.C. Freeman Expanding the cellular molecular chaperone network through the ubiquitous cochaperones Biochim. Biophys. Acta 823 2014 668 673
21. J. Li Integration of the accelerator Aha1 in the Hsp90 co-chaperone cycle Nat. Struct. Mol. Biol. 20 2013 326 331
22. J.M. Eckl Cdc37 (cell division cycle 37) restricts Hsp90 (heat shock protein 90) motility by interaction with N-terminal and middle domain binding sites J. Biol. Chem. 288 2013 16032 16042
23. M.C. Smith The E3 ubiquitin ligase CHIP and the molecular chaperone Hsc70 form a dynamic, tethered complex Biochemistry 52 2013 5354 5364
24. J.N. Rauch, and J.E. Gestwicki Binding of human nucleotide exchange factors to heat shock protein 70 (Hsp70) generates functionally distinct complexes in vitro J. Biol. Chem. 289 2014 1402 1414
25. F. Cappello Hsp60 expression, new locations, functions and perspectives for cancer diagnosis and therapy Cancer Biol. Ther. 7 2008 801 809
26. C. Campanella The odyssey of Hsp60 from tumor cells to other destinations includes plasma membrane-associated stages and Golgi and exosomal protein-trafficking modalities PLoS ONE 7 2012 e42008
27. G.S. Butler, and C.M. Overall Proteomic identification of multitasking proteins in unexpected locations complicates drug targeting Nat. Rev. Drug Discov. 8 2009 935 948
28. S.V. Alarcon Tumor-intrinsic and tumor-extrinsic factors impacting hsp90-targeted therapy Curr. Mol. Med. 12 2012 1125 1141
29. Y. Hua Molecular chaperone gp96 is a novel therapeutic target of multiple myeloma Clin. Cancer Res. 19 2013 6242 6251
30. C.W. Shu, and C.M. Huang HSP70s: from tumor transformation to cancer therapy Clin. Med. Oncol. 2 2008 335 345
31. A.S. Lee Glucose-regulated proteins in cancer: molecular mechanisms and therapeutic potential Nat. Rev. Cancer 14 2014 263 276
32. P.D. Patel Paralog-selective Hsp90 inhibitors define tumor-specific regulation of HER2 Nat. Chem. Biol. 9 2013 677 684
33. M. Marzec GRP94: an HSP90-like protein specialized for protein folding and quality control in the endoplasmic reticulum Biochim. Biophys. Acta 1823 2012 774 787
34. A. Rasola Mitochondrial oxidative phosphorylation TRAP(1)ped in tumor cells Trends Cell Biol. 24 2014 455 463
35. K.A. Krukenberg Conformational dynamics of the molecular chaperone Hsp90 Q. Rev. Biophys. 44 2011 229 255
36. F. Stricher HSPA8/HSC70 chaperone protein: structure, function, and chemical targeting Autophagy 9 2013 1937 1954
37. M. Daugaard The heat shock protein 70 family: highly homologous proteins with overlapping and distinct functions FEBS Lett. 581 2007 3702 3710
38. M.E. Murphy The HSP70 family and cancer Carcinogenesis 34 2013 1181 1188
39. A. Pace Hsp60, a novel target for antitumor therapy: structure-function features and prospective drugs design Curr. Pharm. Design 19 2013 2757 2764
40. A.P. Arrigo HspB1, HspB5 and HspB4 in human cancers: potent oncogenic role of some of their client proteins Cancers 6 2014 333 365
41. G. Jego Targeting heat shock proteins in cancer Cancer Lett. 332 2013 275 285
42. J.N. Sterrenberg Human DNAJ in cancer and stem cells Cancer Lett. 312 2011 129 142
43. L. Shaner, and K.A. Morano All in the family: atypical Hsp70 chaperones are conserved modulators of Hsp70 activity Cell Stress Chaperones 12 2007 1 8
44. S. Yamamoto ATPase activity and ATP-dependent conformational change in the co-chaperone HSP70/HSP90-organizing protein (HOP) J. Biol. Chem. 289 2014 9880 9886
45. R.U. Mattoo Hsp110 is a bona fide chaperone using ATP to unfold stable misfolded polypeptides and reciprocally collaborate with Hsp70 to solubilize protein aggregates J. Biol. Chem. 288 2013 21399 21411
46. R.T. Knapp Hsp70 cochaperones HspBP1 and BAG-1 M differentially regulate steroid hormone receptor function PLoS ONE 9 2014 e85415
47. J.M. Eckl, and K. Richter Functions of the Hsp90 chaperone system: lifting client proteins to new heights Int. J. Biochem. Mol. Biol. 4 2013 157 165
48. D.F. Smith Dynamics of heat shock protein 90-progesterone receptor binding and the disactivation loop model for steroid receptor complexes Mol. Endocrinol. 7 1993 1418 1429
49. J. Li, and J. Buchner Structure, function and regulation of the hsp90 machinery Biomed. J. 36 2013 106 117
50. C. Prodromou The 'active life' of Hsp90 complexes Biochim. Biophys. Acta 1823 2012 614 623
51. J. Li The Hsp90 chaperone machinery: conformational dynamics and regulation by co-chaperones Biochim. Biophys. Acta 1823 2012 624 635
52. M. Mollapour, and L. Neckers Post-translational modifications of Hsp90 and their contributions to chaperone regulation Biochim. Biophys. Acta 1823 2012 648 655
53. R.K. Kancha Analysis of conformational determinants underlying HSP90-kinase interaction PLoS ONE 8 2013 e68394
54. M. Taipale Chaperones as thermodynamic sensors of drug-target interactions reveal kinase inhibitor specificities in living cells Nat. Biotechnol. 31 2013 630 637
55. J.P. Lambert Mapping differential interactomes by affinity purification coupled with data-independent mass spectrometry acquisition Nat. Methods 10 2013 1239 1245
56. K. Beebe Posttranslational modification and conformational state of Heat Shock Protein 90 differentially affect binding of chemically diverse small molecule inhibitors Oncotarget 4 2013 1065 1074
57. M. Mollapour Asymmetric Hsp90 N domain SUMOylation recruits Aha1 and ATP-competitive inhibitors Mol. Cell 53 2014 317 329
58. L. Neckers Geldanamycin as a potential anti-cancer agent: its molecular target and biochemical activity Invest. New Drugs 17 1999 361 373
59. A.K. Voss Mice lacking HSP90beta fail to develop a placental labyrinth Development 127 2000 1 11
60. J.S. Ross Targeted therapies for cancer 2004 Am. J. Clin. Pathol. 122 2004 598 609
61. K. Jhaveri Heat shock protein 90 inhibitors in the treatment of cancer: current status and future directions Expert Opin. Invest. Drugs 23 2014 611 628
62. A. Kamal A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors Nature 425 2003 407 410
63. U. Nayar Targeting the Hsp90-associated viral oncoproteome in gammaherpesvirus-associated malignancies Blood 122 2013 2837 2847
64. A. Rodina Affinity purification probes of potential use to investigate the endogenous Hsp70 interactome in cancer ACS Chem. Biol. 9 2014 1698 1705
65. K. Sharma Quantitative proteomics reveals that Hsp90 inhibition preferentially targets kinases and the DNA damage response Mol. Cell. Proteomics 11 2012 1 12
66. H.J. Patel Advances in the discovery and development of heat-shock protein 90 inhibitors for cancer treatment Expert Opin. Drug Discov. 6 2011 559 587
67. K. Jhaveri Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers Biochim. Biophys. Acta 1823 2012 742 755
68. A. Rousaki Allosteric drugs: the interaction of antitumor compound MKT-077 with human Hsp70 chaperones J. Mol. Biol. 411 2011 614 632
69. X. Wang HSP27, 70 and 90, anti-apoptotic proteins, in clinical cancer therapy Int. J. Oncol. 45 2014 18 30
70. L. Neckers, and Pm Workman Hsp90 molecular chaperone inhibitors: are we there yet? Clin. Cancer Res. 18 2012 64 76
71. A. Carman Regulatory chaperone complexes in neurodegenerative diseases: a perspective on therapeutic intervention Curr. Alzheimer Res. 11 2014 59 68
72. A. Silva-Fernandes Chronic treatment with 17-DMAG improves balance and coordination in a new mouse model of Machado-Joseph disease Neurotherapeutics 11 2014 433 449
73. N.R. McFarland Chronic treatment with novel small molecule Hsp90 inhibitors rescues striatal dopamine levels but not alpha-synuclein-induced neuronal cell loss PLoS ONE 9 2014 e86048
74. L.J. Blair Accelerated neurodegeneration through chaperone-mediated oligomerization of tau J. Clin. Invest. 123 2013 4158 4169
75. J. Gao Inhibition of HSP90 attenuates porcine reproductive and respiratory syndrome virus production in vitro Virol. J. 11 2014 17
76. X. Sun Hsp90 inhibitor 17-DMAG decreases expression of conserved herpesvirus protein kinases and reduces virus production in Epstein-Barr virus-infected cells J. Virol. 87 2013 10126 10138
77. I. Anderson Heat shock protein 90 controls HIV-1 reactivation from latency Proc. Natl. Acad. Sci. U.S.A. 111 2014 E1528 E1537
78. R. Geller Broad action of Hsp90 as a host chaperone required for viral replication Biochim. Biophys. Acta 1823 2012 698 706
79. T. O'Meara, and L.E. Cowen Hsp90-dependent regulatory circuitry controlling temperature-dependent fungal development and virulence Cell. Microbiol. 16 2014 473 481
80. T. Seeger-Nukpezah Inhibiting the HSP90 chaperone slows cyst growth in a mouse model of autosomal dominant polycystic kidney disease Proc. Natl. Acad. Sci. U.S.A. 110 2013 12786 12791
81. A. Ambade Pharmacological inhibition of heat shock protein 90 alleviates steatosis and macrophage activation in murine acute and chronic alcoholic liver injury J. Hepatol. 2014 10.1016/j.jhep.2014.05.024
82. S. Desarzens Hsp90 blockers inhibit adipocyte differentiation and fat mass accumulation PLoS ONE 9 2014 e94127
83. K. Stenderup Debio 0932, a new oral Hsp90 inhibitor, alleviates psoriasis in a xenograft transplantation model Acta Derm. Venereol. 2014 10.2340/00015555-1838
84. H.J. Cho A small molecule that binds to an ATPase domain of Hsc70 promotes membrane trafficking of mutant cystic fibrosis transmembrane conductance regulator J. Am. Chem. Soc. 133 2011 20267 20276
85. T. Taldone Experimental and structural testing module to analyze paralogue-specificity and affinity in the Hsp90 inhibitors series J. Med. Chem. 56 2013 6803 6818
86. J.T. Ernst Identification of novel HSP90alpha/beta isoform selective inhibitors using structure-based drug design. demonstration of potential utility in treating CNS disorders such as Huntington's disease J. Med. Chem. 57 2014 3382 3400
87. R.M. Immormino Different poses for ligand and chaperone in inhibitor-bound Hsp90 and GRP94: implications for paralog-specific drug design J. Mol. Biol. 388 2009 1033 1042
88. J.T. Ernst Correlation between chemotype-dependent binding conformations of HSP90alpha/beta and isoform selectivity-Implications for the structure-based design of HSP90alpha/beta selective inhibitors for treating neurodegenerative diseases Bioorg. Med. Chem. Lett. 24 2014 204 208
89. I. Gomez-Monterrey Heat shock protein 90 inhibitors as therapeutic agents Recent Pat. Anticancer Drug Discov. 19 2011 684 692
90. R.L. Matts A systematic protocol for the characterization of Hsp90 modulators Bioorg. Med. Chem. 19 2011 684 692
91. D.S. Williamson Novel adenosine-derived inhibitors of 70 kDa heat shock protein, discovered through structure-based design J. Med. Chem. 52 2009 1510 1513
92. A.T. Macias Adenosine-derived inhibitors of 78 kDa glucose regulated protein (Grp78) ATPase: insights into isoform selectivity J. Med. Chem. 54 2011 4034 4041
93. A. Rodina Identification of an allosteric pocket on human hsp70 reveals a mode of inhibition of this therapeutically important protein Chem. Biol. 20 2013 1469 1480
94. L. Chang Chemical screens against a reconstituted multiprotein complex: myricetin blocks DnaJ regulation of DnaK through an allosteric mechanism Chem. Biol. 18 2011 210 221
95. J.I. Leu A small molecule inhibitor of inducible heat shock protein 70 Mol. Cell 36 2009 15 27
96. F. Cappello Hsp60 chaperonopathies and chaperonotherapy: targets and agents Expert Opin. Ther. Targets 18 2014 185 208
97. E. Chapman A small molecule inhibitor selective for a variant ATP-binding site of the chaperonin GroEL Bioorg. Med. Chem. Lett. 19 2009 811 813
98. Y. Nagumo Epolactaene binds human Hsp60 Cys442 resulting in the inhibition of chaperone activity Biochem. J. 387 2005 835 840
99. R. Kityk Structure and dynamics of the ATP-bound open conformation of Hsp70 chaperones Mol. Cell 48 2012 863 874
100. K.L. Soldano Structure of the N-terminal domain of GRP94. Basis for ligand specificity and regulation J. Biol. Chem. 278 2003 48330 48338
101. E.R. Zuiderweg Allostery in the Hsp70 chaperone proteins Topics Curr. Chem. 328 2013 99 153
102. A.S. Duerfeldt Development of a Grp94 inhibitor J. Am. Chem. Soc. 134 2012 9796 9804
103. Y. Nishiya Drug-target identification from total cellular lysate by drug-induced conformational changes Anal. Biochem. 385 2009 314 320
104. I.O. Ebong Heterogeneity and dynamics in the assembly of the heat shock protein 90 chaperone complexes Proc. Natl. Acad. Sci. U.S.A. 108 2011 17939 17944
105. Y. Kang Heat shock protein 70 inhibitors. 1. 2,5′-thiodipyrimidine and 5-(phenylthio)pyrimidine acrylamides as irreversible binders to an allosteric site on heat shock protein 70 J. Med. Chem. 57 2014 1188 1207
106. T. Taldone Heat shock protein 70 inhibitors. 2. 2,5′-thiodipyrimidines, 5-(phenylthio)pyrimidines, 2-(pyridin-3-ylthio)pyrimidines, and 3-(phenylthio)pyridines as reversible binders to an allosteric site on heat shock protein 70 J. Med. Chem. 57 2014 1208 1224
107. R. Schlecht Functional analysis of Hsp70 inhibitors PLoS ONE 8 2013 e78443
108. B.H. Kang Regulation of tumor cell mitochondrial homeostasis by an organelle-specific Hsp90 chaperone network Cell 131 2007 257 270
109. D.C. Altieri TRAP-1, the mitochondrial Hsp90 Biochim. Biophys. Acta 1823 2012 767 773
110. E. Caldas-Lopes Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models Proc. Natl. Acad. Sci. U.S.A. 106 2009 8368 8373
111. R. Bao CUDC-305, a novel synthetic HSP90 inhibitor with unique pharmacologic properties for cancer therapy Clin. Cancer Res. 15 2009 4046 4057
112. K. Lundgren BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90 Mol. Cancer Ther. 8 2009 921 929
113. S. Chandarlapaty SNX2112, a synthetic heat shock protein 90 inhibitor, has potent antitumor activity against HER kinase-dependent cancers Clin. Cancer Res. 14 2008 240 248
114. M.R. Jensen NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models Breast Cancer Res. 10 2008 R33
115. T. Shimamura Ganetespib (STA-9090), a nongeldanamycin HSP90 inhibitor, has potent antitumor activity in in vitro and in vivo models of non-small cell lung cancer Clin. Cancer Res. 18 2012 4973 4980
116. B. Graham The heat shock protein 90 inhibitor, AT13387, displays a long duration of action in vitro and in vivo in non-small cell lung cancer Cancer Sci. 103 2012 522 527
117. A.J. Massey Preclinical antitumor activity of the orally available heat shock protein 90 inhibitor NVP-BEP800 Mol. Cancer Ther. 9 2010 906 919
118. N. Ono Preclinical antitumor activity of the novel heat shock protein 90 inhibitor CH5164840 against human epidermal growth factor receptor 2 (HER2)-overexpressing cancers Cancer Sci. 103 2012 342 349
119. P. Workman Auditing the pharmacological accounts for Hsp90 molecular chaperone inhibitors: unfolding the relationship between pharmacokinetics and pharmacodynamics Mol. Cancer Ther. 2 2003 131 138
120. M. Vilenchik Targeting wide-range oncogenic transformation via PU24FCl, a specific inhibitor of tumor Hsp90 Chem. Biol. 11 2004 787 797
121. B. Havik, and C.R. Bramham Additive viability-loss following hsp70/hsc70 double interference and Hsp90 inhibition in two breast cancer cell lines Oncol. Rep. 17 2007 1501 1510
122. D. Zhou A rat retinal damage model predicts for potential clinical visual disturbances induced by Hsp90 inhibitors Toxicol. Appl. Pharmacol. 273 2007 401 409